Sanofi SA (NYSE:SNY) – Equities researchers at Jefferies Financial Group issued their Q1 2019 earnings estimates for shares of Sanofi in a report issued on Thursday, March 14th. Jefferies Financial Group analyst P. Welford anticipates that the company will post earnings of $0.72 per share for the quarter. Jefferies Financial Group has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Sanofi’s Q2 2019 earnings at $0.66 EPS, Q3 2019 earnings at $1.14 EPS, Q4 2019 earnings at $0.72 EPS, FY2019 earnings at $3.26 EPS, FY2020 earnings at $3.58 EPS, FY2021 earnings at $3.90 EPS, FY2022 earnings at $4.16 EPS and FY2023 earnings at $4.12 EPS.

SNY has been the subject of a number of other research reports. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Friday, January 18th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, January 14th. TheStreet downgraded shares of Sanofi from a “b” rating to a “c+” rating in a report on Thursday, February 7th. HC Wainwright reissued a “buy” rating on shares of Sanofi in a report on Thursday, February 28th. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Friday, November 30th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $51.00.

Sanofi stock opened at $45.09 on Friday. The firm has a market capitalization of $113.09 billion, a price-to-earnings ratio of 14.41, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. Sanofi has a 12 month low of $37.43 and a 12 month high of $45.62.

Sanofi (NYSE:SNY) last released its quarterly earnings data on Thursday, February 7th. The company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The firm had revenue of $9 billion during the quarter, compared to the consensus estimate of $9 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.06 earnings per share.

The company also recently declared an annual dividend, which will be paid on Friday, May 31st. Stockholders of record on Wednesday, May 8th will be issued a dividend of $1.7395 per share. This represents a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. Sanofi’s dividend payout ratio (DPR) is 38.34%.

In other news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.00% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in SNY. Essex Savings Bank bought a new stake in shares of Sanofi during the fourth quarter valued at about $30,000. Claybrook Capital LLC bought a new stake in shares of Sanofi during the fourth quarter valued at about $31,000. Executive Wealth Management LLC bought a new stake in shares of Sanofi during the fourth quarter valued at about $34,000. Berman Capital Advisors LLC bought a new stake in shares of Sanofi during the fourth quarter valued at about $44,000. Finally, Global Retirement Partners LLC raised its stake in shares of Sanofi by 420.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,040 shares of the company’s stock valued at $45,000 after purchasing an additional 840 shares in the last quarter. 7.04% of the stock is owned by institutional investors.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Marijuana Stocks Investing Considerations

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.